MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202411003546 A) filed by Shoolini University Of Biotechnology And Management Sciences, Solan, Himachal Pradesh, on Jan. 18, 2024, for 'a superparamagnetic nano formulation for brain tumour therapy and method of preparing the same.'
Inventor(s) include Himanshu; Dr. Deepak Kapoor; and Dr. Deepak Kumar.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present invention discloses synthesis of superparamagnetic iron oxide nanoparticles (SPIONs) as a carrier for targeted delivery of the anticancer drug Docetaxel to the brain. The formulation, G-SPIO/DTX-PLGA-NPs, demonstrated optimized characteristics with a particle size of 190 nm, Zeta potential of -27.6 mV, and controlled drug release. In vitro studies showed significantly enhanced cytotoxicity (84.71%) compared to free Docetaxel (72.29%), with a 3.39-fold reduction in IC50 values. In vivo, magnetically guided G-SPIO/DTX-PLGA-NPs exhibited a brain tissue concentration 21.94-fold higher than free Docetaxel and 1.46-fold higher than the non-guided formulation, showcasing the potential for improved brain tumor therapy with reduced systemic toxicity."
Disclaimer: Curated by HT Syndication.
